tirzepatide/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases body mass
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“The pooled data analysis showed substantial weight reduction in all three tirzepatide doses compared to the placebo group.”
Quoted verbatim from Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.. - Study
- meta-analysis
- Dose
- 5, 10 and 15 mg once weekly
- Population
- Adults with or without type 2 diabetes in seven placebo-controlled trials, 12 to 72 weeks; all three doses
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.2024PMID:38850440Industry fundedPermalink
Keep reading
- Everything the graph holds on tirzepatide
- Every compound studied against Body mass
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PR6H38D1SBSSTPHC168X02